Related Experiment Videos

Mortality associated with wines, beers, and spirits. Inappropriate groups were used to calculate relative risk

V Wilson, D Gregson, E Smyth

BMJ (Clinical Research Ed.)

|October 28, 1995

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

DKN-01 and atezolizumab as second- or third-line therapy in advanced oesophagogastric adenocarcinoma: the WAKING trial.

ESMO gastrointestinal oncology·2026

Zolbetuximab plus pembrolizumab and chemotherapy in CLDN18.2-positive, HER2-negative, PD-L1-positive gastric or gastroesophageal junction adenocarcinoma: randomized, double-blind, phase III LUCERNA trial.

ESMO gastrointestinal oncology·2026

Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation.

ESMO open·2026

DESTINY-Gastric05 phase III trial of first-line trastuzumab deruxtecan, chemotherapy, and pembrolizumab in HER2-positive gastric or gastroesophageal junction cancer.

ESMO gastrointestinal oncology·2026

Impact and effective management of nausea/vomiting on patients treated with zolbetuximab + chemotherapy: insights from the phase III SPOTLIGHT and GLOW studies.

ESMO open·2026

Evaluating trastuzumab deruxtecan in patients with gastrooesophageal adenocarcinoma who are ctDNA and HER2 positive: DECIPHER.

ESMO gastrointestinal oncology·2026

See all related articles